Big data can benefit rheumatology research. But according to experts at the 2018 ACR/ARHP Annual Meeting, the data must first be accessible, interoperable and shareable…
Search results for: Big data
Big Data May Shift Reference Ranges for Some Lab Tests
How will big data mined from huge sample sizes in research cohorts, electronic health records, personal health data (e.g., heart rates from Fitbits) and insurance claim data sets change the way physicians interpret something as simple as complete blood count (CBC) test results for individual patients? According to the authors of a paper in the…
The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.
RHIT Chair William F. Harvey, MD, MSc, Promotes the Use of Health Data to Improve Practice and Care
As the new chair of the Registries & Health Information Technology Committee, William F. Harvey, MD, MSc, hopes to expand representation of patient diversity in the RISE registry and increase the use of registry data for research.
New Study Identifies How Big a Role Diet Plays in Hyperuricemia
Living like a king has its price. And while kings and queens are primarily something of yesteryear, the vast majority of those living in reasonably wealthy nations can now live like kings. Now, back to that price. Gout, once known as the disease of kings, has been around at least since the time of the…
Google Signs Healthcare Data & Cloud Computing Deal with Ascension
(Reuters)—Alphabet Inc.’s Google signed its biggest cloud computing customer in healthcare yet, according to an announcement on Monday, gaining with the deal datasets that could help it tune potentially lucrative artificial intelligence tools. The Wall Street Journal earlier reported Google teaming up with Ascension to collect personal health-related information of millions of Americans across 21…
Using RISE Data in Research
The ACR’s RISE registry offers answers on real-world experience to researchers.
Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases
NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
Healthcare Data Hacking May Lead to Identity Thefts
(Reuters Health)—More than 70% of healthcare data breaches in the U.S. have involved sensitive demographic or financial information that could fuel identity theft, a new study suggests. When a healthcare company is hacked, criminals gain access not only to health information, but also to demographic and financial data that could compromise patients’ privacy and financial…
High-Dose Teriparatide with Denosumab Gives Bigger BMD Boost
NEW YORK (Reuters Health)—Adding high-dose teriparatide to denosumab therapy leads to substantially greater increases in bone-mineral density (BMD) than combination therapy with low-dose teriparatide, a new phase 4 study shows. “The combination of denosumab and teriparatide, particularly with high-dose teriparatide of 40 ug daily, may be of benefit to patients at very high risk of…
- 1
- 2
- 3
- …
- 54
- Next Page »